PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery

2016 ◽  
Vol 43 ◽  
pp. 14-29 ◽  
Author(s):  
Duy Luong ◽  
Prashant Kesharwani ◽  
Rahul Deshmukh ◽  
Mohd Cairul Iqbal Mohd Amin ◽  
Umesh Gupta ◽  
...  
2018 ◽  
Vol 12 ◽  
pp. 177-190 ◽  
Author(s):  
Fereydoon Abedi-Gaballu ◽  
Gholamreza Dehghan ◽  
Maryam Ghaffari ◽  
Reza Yekta ◽  
Soheil Abbaspour-Ravasjani ◽  
...  

2006 ◽  
Vol 120 (5) ◽  
pp. 3004-3004
Author(s):  
Rinat Esenaliev ◽  
Olga Chumakova ◽  
Inga Cicenaite ◽  
Shilla Chakrabarty ◽  
Mark Evers ◽  
...  

2019 ◽  
Vol 26 (38) ◽  
pp. 6834-6850 ◽  
Author(s):  
Mohammad Omaish Ansari ◽  
Kalamegam Gauthaman ◽  
Abdurahman Essa ◽  
Sidi A. Bencherif ◽  
Adnan Memic

: Nanobiotechnology has huge potential in the field of regenerative medicine. One of the main drivers has been the development of novel nanomaterials. One developing class of materials is graphene and its derivatives recognized for their novel properties present on the nanoscale. In particular, graphene and graphene-based nanomaterials have been shown to have excellent electrical, mechanical, optical and thermal properties. Due to these unique properties coupled with the ability to tune their biocompatibility, these nanomaterials have been propelled for various applications. Most recently, these two-dimensional nanomaterials have been widely recognized for their utility in biomedical research. In this review, a brief overview of the strategies to synthesize graphene and its derivatives are discussed. Next, the biocompatibility profile of these nanomaterials as a precursor to their biomedical application is reviewed. Finally, recent applications of graphene-based nanomaterials in various biomedical fields including tissue engineering, drug and gene delivery, biosensing and bioimaging as well as other biorelated studies are highlighted.


2016 ◽  
Vol 20 (28) ◽  
pp. 2949-2959 ◽  
Author(s):  
Mahdi Karimi ◽  
Seyed Basri ◽  
Manouchehr Vossoughi ◽  
Parvin Pakchin ◽  
Hamed Mirshekari ◽  
...  

Pharmaceutics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 940
Author(s):  
Chaojie Zhu ◽  
Zhiheng Ji ◽  
Junkai Ma ◽  
Zhijie Ding ◽  
Jie Shen ◽  
...  

Cancer is one of the most devastating and ubiquitous human diseases. Conventional therapies like chemotherapy and radiotherapy are the most widely used cancer treatments. Despite the notable therapeutic improvements that these measures achieve, disappointing therapeutic outcome and cancer reoccurrence commonly following these therapies demonstrate the need for better alternatives. Among them, bacterial therapy has proven to be effective in its intrinsic cancer targeting ability and various therapeutic mechanisms that can be further bolstered by nanotechnology. In this review, we will discuss recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems in cancer treatment. Therapeutic mechanisms of these hybrid nanoformulations are highlighted to provide an up-to-date understanding of this emerging field.


Molecules ◽  
2021 ◽  
Vol 26 (10) ◽  
pp. 2924
Author(s):  
Cláudia Camacho ◽  
Helena Tomás ◽  
João Rodrigues

The DACHPtCl2 compound (trans-(R,R)-1,2-diaminocyclohexanedichloroplatinum(II)) is a potent anticancer drug with a broad spectrum of activity and is less toxic than oxaliplatin (trans-l-diaminocyclohexane oxalate platinum II), with which it shares the active metal fragment DACHPt. Nevertheless, due to poor water solubility, its use as a chemotherapeutic drug is limited. Here, DACHPtCl2 was conjugated, in a bidentate form, with half-generation PAMAM dendrimers (G0.5–G3.5) with carboxylate end-groups, and the resulting conjugates were evaluated against various types of cancer cell lines. In this way, we aimed at increasing the solubility and availability at the target site of DACHPt while potentially reducing the adverse side effects. DNA binding assays showed a hyperchromic effect compatible with DNA helix’s disruption upon the interaction of the metallodendrimers and/or the released active metallic fragments with DNA. Furthermore, the prepared DACHPt metallodendrimers presented cytotoxicity in a wide set of cancer cell lines used (the relative potency regarding oxaliplatin was in general high) and were not hemotoxic. Importantly, their selectivity for A2780 and CACO-2 cancer cells with respect to non-cancer cells was particularly high. Subsequently, the anticancer drug 5-FU was loaded in a selected metallodendrimer (the G2.5COO(DACHPt)16) to investigate a possible synergistic effect between the two drugs carried by the same dendrimer scaffold and tested for cytotoxicity in A2780cisR and CACO-2 cancer cell lines. This combination resulted in IC50 values much lower than the IC50 for 5-FU but higher than those found for the metallodendrimers without 5-FU. It seems, thus, that the metallic fragment-induced cytotoxicity dominates over the cytotoxicity of 5-FU in the set of considered cell lines.


Biomaterials ◽  
2016 ◽  
Vol 82 ◽  
pp. 194-207 ◽  
Author(s):  
Xiaofei Liang ◽  
Bizhi Shi ◽  
Kai Wang ◽  
Mingliang Fan ◽  
Dejin Jiao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document